Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
All news
Biotechnology
BioCryst Pharmaceuticals revealed on Friday that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted oral, once-daily berotralstat a positive scientific opinion through the Early Access to Medicines Scheme (EAMS). 31 October 2020
Biotechnology
Biogen and Eisai have announced that the European Medicines Agency (EMA) has confirmed it has accepted for review the Marketing Authorization Application (MAA) for aducanumab, an investigational treatment for Alzheimer’s disease. 30 October 2020
Biotechnology
Stock in US biotech Moderna ended the day up nearly 8.5% on Thursday, following a business update in which the firm said it was “actively preparing” for the launch of its COVID-19 vaccine. 30 October 2020
Biotechnology
The Japanese subsidiary of US pharma major Eli Lilly is partnering with Daiichi Sankyo on the commercialization of galcanezumab in Japan. 30 October 2020
Biotechnology
Danish biotech Genmab and ADC Therapeutics have amended the terms of their agreement for the Swiss company’s continued development and commercialization of camidanlumab tesirine (Cami). 30 October 2020
Biotechnology
Shares in Japanese drugmaker Takeda slipped by 6% on Friday after the firm presented its latest financial results. 30 October 2020
Biotechnology
A positive reimbursement decision in the UK means that Novo Nordisk’s Saxenda (liraglutide) will be available through the country’s national healthcare provider as a weight management treatment. 30 October 2020
Biotechnology
The European Patent Office (EPO) Technical Boards of Appeal has ruled in French pharma major Sanofi and US partner Regeneron Pharmaceutical’s favor, invalidating certain claims of Amgen’s European patent (EP 2 215 124) directed to PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies relevant to Praluent (alirocumab). 30 October 2020
Biotechnology
insitro, a California-based machine-learning driven drug discovery and development company, has entered into a five-year, discovery collaboration with US pharma major Bristol Myers Squibb focused on the discovery and development of novel therapies for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). 29 October 2020
Biotechnology
Vedere Bio, a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision, has announced that it has been acquired by Novartis. 29 October 2020
Biotechnology
US biotech giant Amgen announced financial results for the third quarter of 2020 at close of market on Wednesday, showing that total revenues increased 12% to $6.42 billion, just ahead of analyst estimates of $6.38 billion, driven by higher volume growth, partially offset by lower net selling prices and the effects of the COVID-19 pandemic. 29 October 2020
Biotechnology
Swiss pharma major Novartis has strengthened its case for a US Food and Drug Administration (FDA) approval of Cosentyx (secukinumab) in pediatric psoriasis. 29 October 2020
Biotechnology
Swiss pharma giant Roche today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. 29 October 2020
Biotechnology
Regeneron Pharmaceuticals’ shares edged up 2.3% to $580.00 pre-market after the US biotech announced positive, prospective results from an ongoing Phase II/III seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. 29 October 2020
Biotechnology
Top-line results from the Phase IIIb PONENTE study show that 62% of people with severe asthma were able to stop using oral corticosteroids (OCS) when treated with Fasenra (benralizumab). 29 October 2020
Biotechnology
Japan’s largest drugmaker Takeda Pharmaceutical said today that it will import and distribute 50 million doses of Moderna’s COVID-19 vaccine candidate, mRNA-1273, starting in the first half of 2021, pending licensure in Japan. 29 October 2020
Biotechnology
Flagship Pioneering has announced the unveiling of Senda Biosciences, a therapeutics platform company leveraging insights into the molecular connections between humans and co-evolved non-human species. 29 October 2020
Biotechnology
Eli Lilly has announced an initial agreement with the US government to supply 300,000 vials of bamlanivimab 700mg for $375 million. 28 October 2020
Biotechnology
US clinical-stage biotech Scholar Rock skyrocketed 119% by close of trading Tuesday and was up a further 13.9% to $34.16 this morning, after it released stunning trial results on its lead investigational drug SRK-015 and announced a public offering of shares. 28 October 2020
Biotechnology
Swiss firm Molecular Partners’ shares were up almost 30% at 19.92 Swiss francs by early afternoon, after it a collaboration with pharma giant Novartis in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin program, consisting of two therapeutic candidates, MP0420 and MP0423. 28 October 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze